Thank you for Subscribing to Eldercare Review Weekly Brief
Eldercare Review | Tuesday, November 19, 2024
Dementia care is on the brink of a significant transformation, driven by recent developments in cost-effective and scalable blood tests for diagnosis. This article discusses the clinical biomarker tools and technologies for dementia care.
Fremont, CA: Dementia care is poised for a significant transformation due to recent advancements in affordable and scalable blood tests for diagnosis, alongside the approval of pioneering amyloid-reducing therapies such as lecanemab and donanemab. For the first time, it is feasible to alter the trajectory of dementia, and upcoming therapies in development aim to enhance these effects even further. Nevertheless, these treatments must be administered with caution due to the associated costs and potential for serious side effects. Timely identification of patients and precise treatment monitoring are crucial to ensure that these therapies are provided to the appropriate individuals, thereby maximizing the likelihood of favorable outcomes.
The Challenge with Imaging Tests in Dementia Care
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Imaging currently presents a significant challenge in the realm of dementia care. While PET scans are recognized as the gold standard for diagnosis—and are indeed a prerequisite for initiating amyloid therapy—there is a shortage of both PET scanners and radiologists qualified to interpret these scans, which hampers the ability to meet the surging demand triggered by the recent approval of new medications. For instance, one facility in the United States has reported a fivefold increase in referrals for diagnostic imaging since the approval of donanemab. Nonetheless, Quantified Imaging asserts that imaging will continue to play a crucial role in the standard care pathway for dementia due to its actionable insights. Although blood tests can effectively detect the presence of disease years before symptoms manifest, only imaging can provide a view of the brain to determine the appropriate timing for treatment initiation. Furthermore, imaging is essential for assessing the brain's response to treatment, which is vital given the known risks associated with such therapies.
Unifying Blood and Imaging Biomarkers
No single technology can independently address the challenges posed by dementia. Blood tests will play a vital role in the overall solution, enabling more individuals to receive precise diagnoses and initiate treatment much more swiftly than is currently feasible. However, these tests alone cannot provide the necessary insights into the effects of the disease on brain tissue, which are essential for customizing treatment to the individual, thereby reducing risks and enhancing benefits. In light of this, Quantified Imaging is working on technologies that integrate blood and imaging biomarkers into a cohesive diagnosis and treatment monitoring framework. A vital component of this initiative is a predictive model of brain health tailored to a patient's age, sex, and anatomical characteristics. Presently undergoing testing at a prominent brain health clinic in the UK, this model is set to evolve by incorporating patients' blood test results to enhance personalization further. Ultimately, it is predicted that this technology can be transformed into a comprehensive assessment of overall brain health, significantly improving our capacity to prevent, monitor, and treat a range of neurological disorders.
More in News